According to a report from Toronto Online, the Ottawa Hospital Research Institute (OHRI), the University of Ottawa, Jennerex, and several other research institutions have recently published articles in the famous scientific journal Nature The positive results of the first clinical trial of oncolytic virus anticancer therapy. The experimental results show for the first time that the anti-cancer virus that enters the human body by intravenous injection can continue to spread and spread in the tumor without harming normal human tissues. This is also the first experimental proof that the foreign-targeted genes showed selective tumor response after intravenous injection. 23 patients participated in this clinical trial (of which 7 were from Ottawa Hospital). These patients are in advanced stages of cancer, cancer cells have spread to multiple organs throughout the body, and have lost response to general therapy. Each patient received an intravenous infusion of a virus called JX-594 at the beginning of the experiment, grouped at five different dose levels, and received a biopsy after 8 to 10 days. In the two groups that received the highest and second-highest injection doses, 7 out of 8 (87%) in each group had anti-cancer virus replication in their tumors, but not in normal human tissues. All patients showed signs of selective tumor response to foreign targeted genes that were attached to the virus to help detect the virus. The experiment also showed that JX-594 virus can survive in different doses of injection, the most common side effects are mild to moderate cold-like symptoms, and the duration does not exceed one day. Ningbo XISXI E-commerce Co., Ltd , https://www.petspetskitty.com